Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United States-Reference-Cited by-同舟云学术

Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United States

Published:2024-05-25 Issue:7 Volume:13 Page:1501-1514
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Yi Zinan^ORCID,Johnson Kelly D.,Owusu-Edusei Kwame

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40121-024-00988-1.pdf

Reference41 articles.

1. Global Burden of Disease 2016. Lower respiratory infections collaborators, estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191–210.

2. Centers for Disease Control and Prevention. Chapter 11: Pneumococcal, manual for the surveillance of vaccine-preventable diseases. 2020. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html. Accessed 2023 May.

3. Ogilvie I, Khoury AE, Cui Y, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009;27(36):4891–904.

4. Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE. 2013;8(4):e60273.

5. Pelton SI, Bornheimer R, Doroff R, et al. Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization. Clin Infect Dis. 2019;68(11):1831–8.